Company Valeo Pharma Inc. Canadian Securities Exchange

VPH

CA91915B1085

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Valeo Pharma Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 03:57:37 2022-03-28 pm EDT			5-day change	1st Jan Change
0.66 ^CAD	-.--%		+1.54%	-10.81%

Mar. 22	Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	CI
Mar. 15	Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

CAD in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals and Hospital Specialty Products 100.0 %	28	100.0 %	54	100.0 %	+94.31%

CAD in Million	2022	Weight	2023	Weight	Delta
Canada 100.0 %	28	100.0 %	54	100.0 %	+94.31%

Managers	Title	Age	Since
Steven Saviuk FOU	Founder	65	03-03-26
Pascal Tougas DFI	Director of Finance/CFO	-	Nov. 19
Nelly Komari CTO	Chief Tech/Sci/R&D Officer	-	21-05-31
Frédéric Dumais IRC	Investor Relations Contact	-	19-05-31
Pierre Ecclestone PRN	Corporate Officer/Principal	-	23-07-31
Kyle Steiger PRN	Corporate Officer/Principal	-	22-08-29
David Newell SAM	Sales & Marketing	-	11-10-31
Nathalie Therrien LAW	General Counsel	56	16-01-24
Guy-Paul Allard LAW	General Counsel	56	16-03-31
Helen Saviuk PRN	Corporate Officer/Principal	71	07-12-31

Members of the board	Title	Age	Since
Richard MacKay CHM	Chairman	89	18-07-24
Steven Saviuk FOU	Founder	65	03-03-26
Marc Léger BRD	Director/Board Member	65	22-04-26
Richard Lajoie BRD	Director/Board Member	-	Nov. 06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	98,675,427	52,181,062 ( 52.88 %)	0	52.88 %

Name	Equities	%	Valuation
MANITEX CAPITAL INC. 25.72 %	25,372,987	25.72 %	3 M $
Richard MacKay 16.44 %	16,222,751	16.44 %	2 M $
Investissement Québec 7.239 %	7,142,857	7.239 %	892 857 $
Steven Saviuk 3.882 %	3,829,890	3.882 %	478 736 $
Luc Mainville 3.082 %	3,041,055	3.082 %	380 132 $
Helen Saviuk 2.603 %	2,568,324	2.603 %	321 041 $
Marc Léger 2.363 %	2,331,414	2.363 %	291 427 $
Simcor Canada Holdings, Inc. 1.717 %	1,694,145	1.717 %	211 768 $
Jeffrey Skinner 1.421 %	1,402,150	1.421 %	175 269 $
Nathalie Therrien 1.377 %	1,358,369	1.377 %	169 796 $

Valeo Pharma, Inc.

16667 Hymus Boulevard

H9H 4R9, Kirkland

+514-694-0150

http://www.valeopharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.085 CAD

Average target price

0.5 CAD

Spread / Average Target

+488.24%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals